Prot #172-0151-202: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than

Project: Research project

Project Details

Effective start/end date5/16/135/16/16


  • Therapeutics, Inc. (Prot #172-0151-202 // Prot #172-0151-202)
  • PreCision Dermatology, Inc. (Prot #172-0151-202 // Prot #172-0151-202)